Get started
Author

Andres A. Gutierrez

Observed names: A A Gutierrez, A.A Gutierrez, A.A. Gutierrez, A.A. Gutiérrez, ANDRES A. GUTIERREZ, Andres A GUTIERREZ, Andres A Gutierrez, Andres Gutierrez, Andrés A Gutiérrez, Andrés A. Gutiérrez
Observed institutions: Hammersmith Hospital, Ajanta Pharma (India), Bristol-Myers Squibb (United States), Secretaria de Salud, Hospital Angeles Pedregal, Instituto Nacional de Rehabilitación, Advaxis (United States), Oculus Innovative Sciences (United States), Oncolytics Biotech (Canada), Universidad Nacional Autónoma de México
OpenAlex ID: A5113555640
Gene therapy for cancer
1992 · A.A Gutierrez, N.R Lemoine, et al. · The Lancet · 157
Gene therapy for cancer using tumour-specific prodrug activation.
1994 · J D Harris, A A Gutierrez, et al. · PubMed · 134
Neurogenesis in the subventricular zone following transcranial magnetic field stimulation and nigrostriatal lesions
2004 · O. Arias‐Carrión, L. Verdugo‐Díaz, et al. · Journal of Neuroscience Research · 109
Microcyntm: a novel super-oxidized water with neutral pH and disinfectant activity
2005 · C. Landa-Solis, D. González-Espinosa, et al. · Journal of Hospital Infection · 105
Progesterone effects on cell growth of U373 and D54 human astrocytoma cell lines
2007 · Gabriela González-Agüero, Andrés A. Gutiérrez, et al. · Endocrine · 78
Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia
2014 · Pamela S. Becker, James M. Foran, et al. · Blood · 61
Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.
2013 · Charles G. Drake, David F. McDermott, et al. · Journal of Clinical Oncology · 55
Activation of a Ca2+‐permeable cation channel by two different inducers of apoptosis in a human prostatic cancer cell line
1999 · Andrés A. Gutiérrez, Juan Manuel Arias, et al. · The Journal of Physiology · 47
ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study
2022 · Mark N Stein, Lawrence Fong, et al. · The Oncologist · 46
PDF
Neutral super-oxidised solutions are effective in killingP. aeruginosabiofilms
2008 · Karin Sauer, Eileen Thatcher, et al. · Biofouling · 38
Effects of pH‐neutral, super‐oxidised solution on human dermal fibroblasts in vitro
2007 · Diana González‐Espinosa, Leafar Pérez‐Romano, et al. · International Wound Journal · 33
PDF
Super-oxidized solution inhibits IgE-antigen-induced degranulation and cytokine release in mast cells
2007 · J. Medina-Tamayo, E. Sánchez-Miranda, et al. · International Immunopharmacology · 32
An Open-label, Three-arm Pilot Study of the Safety and Efficacy of Topical Microcyn Rx Wound Care versus Oral Levofloxacin versus Combined Therapy for Mild Diabetic Foot Infections
2011 · Adam Landsman, Peter A. Blume, et al. · Journal of the American Podiatric Medical Association · 30
A study of REOLYSIN in combination with pembrolizumab and chemotherapy in patients (pts) with relapsed metastatic adenocarcinoma of the pancreas (MAP).
2017 · Devalingam Mahalingam, Christos Fountzilas, et al. · Journal of Clinical Oncology · 24
Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM).
2009 · Ruben Niesvizky, Luhua Wang, et al. · Blood · 23
Vaccine strain Listeria monocytogenes bacteremia occurring 31 months after immunization
2018 · Elias Fares, Cindy B. McCloskey, et al. · Infection · 19
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
2016 · Casey Ager, Matthew Reilley, et al. · Journal for ImmunoTherapy of Cancer · 17
PDF
A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non–small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting.
2022 · Gregory James Gerstner, Suresh S. Ramalingam, et al. · Journal of Clinical Oncology · 15
Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
2014 · Irene M. Ghobrial, Raymond Perez, et al. · Blood · 15
Abstract CT007: Safety and immunogenicity of a personalized neoantigen-Listeria vaccine in cancer patients
2019 · J. Randolph Hecht, Jonathan W. Goldman, et al. · Cancer Research · 12
A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).
2020 · Suresh S. Ramalingam, Tom Stinchcombe, et al. · Journal of Clinical Oncology · 9
RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results.
2023 · Mrinal M. Gounder, Robin Lewis Jones, et al. · Journal of Clinical Oncology · 8
KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel.
2020 · Mark N. Stein, Lawrence Fong, et al. · Journal of Clinical Oncology · 8
A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors.
2013 · Naiyer A. Rizvi, Jeffrey R. Infante, et al. · Journal of Clinical Oncology · 7
A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy.
2021 · Missak Haigentz, Suresh S. Ramalingam, et al. · Journal of Clinical Oncology · 5
Works count: 49
Citation count: 1,115
H-index: 17
I10-index: 20
Year
Topic
Type